Clinical results in the treatment of respiratory infections with moxifloxacin

Drugs of Today

Volumn 36, Issue 4, 2000, Pages 245-253

  Lode, H ^a   Lubasch, A ^a   Raffenberg, M ^a   Mauch, H ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIBIOTIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CEFUROXIME AXETIL; CLARITHROMYCIN; COTRIMOXAZOLE; GREPAFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; PENICILLIN DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SPARFLOXACIN; TROVAFLOXACIN;

ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; CHRONIC BRONCHITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; HUMAN; MAJOR CLINICAL STUDY; META ANALYSIS; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NAUSEA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; REVIEW; SINUSITIS; TREATMENT OUTCOME;

EID: 0034107295     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2000.36.4.570202     Document Type: Review

References (23)

1. ATS: Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, and initial antimicrobial therapy. Am Rev Respir Dis 1993, 148: 1418-26.
2. European Study on Community-acquired Pneumonia Committee. Guidelines for management of adult community-acquired lower respiratory tract infections. Eur Respir J 1998, 11: 986-91.
3. Fine, M.J., Smith, M.A., Carson, C.A. et al. Prognosis and outcomes of patients with community-acquired pneumonia. JAMA 1996, 275: 134-41.
4. Niederman, M.S. Treatment of respiratory infections with quinolones. In: The Quinolones, 2nd Ed. Andreolé, V.T. (Ed.). Academic Press: San Diego 1998, 229-50.
5. Bartlett, J.G. Community-acquired pneumonia in adults: Guidelines for management. The Infectious Diseases Society of America. Clin Infect Dis 1998, 26: 811-38.
6. Ball, P. Therapy for pneumococcal infection at the millennium: Doubts and certainties. Am J Med 1999, 107 (1A): 77-95.
7. Wise, R. A review of the clinical pharmacology of moxifloxacin, a new 8-methoxyquinolone, and its potential relation therapeutic efficacy. Clin Drug Invest 1999, 17: 365-87.
8. Woodcock, J.M., Andrew, J.M., Boswell, F.J. et al. In vitro activity of BAY 12-8039, a new fluoroquinolone. Antimicrob Agents Chemother 1997, 41: 101-6.
9. Fass, R.J. In vitro activity of BAY 12-803, a new 8-methoxyquinolone. Antimicrob Agents Chemother 1997, 41: 1818-24.
10. Bauernfeind, A. Comparison of the antibacterial activities of the quinolones. BAY 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin. J Antimicrob Chemother 1997, 40: 639-51.
11. Schmitz, F.J., Hofmann, B., Hansen, B. et al. Relationship between ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin and moxifloxacin (BAY 12-8039) MICs and mutations in grlA grlB, GyrA and gyrB in 116 unrelated clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 1998, 41: 481-4.
12. Robin, P.M., Hammerschlag, M.R. In vitro activity of a new 8-methoxyquinolone. BAY 12-8038, against Chlamydia pneumoniae. Antimicrob Agents Chemother 1998, 42: 951-2.
13. Bébéar, C.M., Renaudin, H., Boudjadja, A. et al. In vitro activity of BAY 12-8039, a new fluoroquinolone against mycoplasmas. Antimicrob Agents Chemother 1998, 42: 951-2.
14. Ruckdeschel, G., Dalhoff, A. The in vitro activity of moxifloxacin against Legionella species and the effects of medium on susceptibility test results. J Antimicrob Chemother 1999, 43 (Suppl. B): 25-30.
15. Stass, H.H., Dalhoff, A., Kubitza, D. et al. Pharmacokinetics, safety and tolerability of ascending single doses of moxifloxacin, a new 8-methoxyquinolone, administered to healthy subjects. Antimicrob Agents Chemother 1998, 42: 2060-5.
16. Wise, R., Honeybourne, D. Pharmacokinetics and pharmacodynamics of fluoroquinolones in the respiratory tract. Eur Respir J 1999, 14: 221-9.
17. Petipretz, P., Branco Pines, J., Dosedel, J., Rico Mendez, G., Arvis, P. Moxifloxacin (MFX) versus amoxicillin (AMOX) in the treatment of community-acquired suspected pneumococcal pneumonia: A multinational double-blind randomized study. Clin Microbiol Infect 1999, 5(Suppl. 3): Abst P207.
18. Krasemann, C., Meyer, J.M., Springsklee, M. Moxifloxacin (MFX) in community-acquired pneumonia (CAP) - a bacteriologic and clinical meta-analysis. Clin Microbiol Infect 1999, 5(Suppl. 3): Abst P205.
19. Krasemann, C., Meyer, J.M., Springsklee, M. Moxifloxacin (MFX) in acute exacerbations of chronic bronchitis (AECB) - A bacteriologic and clinical meta-analysis. Clin Microbiol Infect 1999, 5(Suppl. 3): Abst P203.
20. Pajchel, G., Tyski, S. Adaptation of capillary electrophoresis for Tazocin analysis. Clin Microbiol Infect 1999, 5(Suppl. 3): Abst P188.
21. Krasemann, C., Meyer, J.M., Springsklee, M. Moxifloxacin (MFX) in acute sinusitis (AS) - A bacteriologic and clinical meta-analysis. Clin Microbiol Infect 1999, 5(Suppl. 3): Abst P204
22. Springsklee, M., Reiter, C.M., Meyer, J.M. Safety and tolerability profile of moxifloxacin. Clin Microbiol Infect 1999, 5(Suppl. 3): P208.
23. Barman Balfour, J.A., Wiseman, L.R. Moxifloxacin. Drugs 1999, 57: 363-73.